Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms
Sufferers with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and particular molecular markers as a surrogate measure of relapse isn’t all the time useful; subsequently, improved techniques to detect early relapse are wanted. We hypothesized that the usage of subsequent technology sequencing (NGS) may very … Read more